Yana Najjar
Clinical trials sponsored by Yana Najjar, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can radiation plus two immunotherapies shrink Hard-to-Treat tumors? Results expected Oct 2026 (estimated)
-
Can radiation plus two immunotherapies shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing whether combining targeted radiation (SBRT) with two immunotherapy drugs—nivolumab and an experimental anti-IL-8 antibody—is safe and potentially effective for people with advanced solid tumors or melanoma that have stopped responding to standard…
Phase 1 • Sponsor: Yana Najjar • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could a diabetes drug boost immunotherapy in advanced melanoma?
Disease control OngoingThis trial investigates whether adding metformin, a common diabetes drug, to the immunotherapy pembrolizumab (Keytruda) can improve treatment for people with advanced melanoma. The study focuses on reversing metabolic problems inside tumors that may weaken immune cells. Participa…
Phase 1 • Sponsor: Yana Najjar • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC